Notes
funded by Amgen
with the first and every chemotherapy cycle
following a febrile neutropenia event
Reference
Fust K, et al. Cost-Effectiveness of Prophylaxis Treatment Strategies for Febrile Neutropenia in Patients With Recurrent Ovarian Cancer. Gynecologic Oncology : 19 Mar 2014. Available from: URL: http://dx.doi.org/10.1016/j.ygyno.2014.03.014
Rights and permissions
About this article
Cite this article
Pegfilgrastim cost effective in recurrent ovarian cancer. PharmacoEcon Outcomes News 700, 9 (2014). https://doi.org/10.1007/s40274-014-1175-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1175-6